Timing of Glaucoma Drainage Device With Boston Keratoprosthesis
Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Mar 10, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best timing for a surgery that helps prevent glaucoma in patients receiving a Boston keratoprosthesis (KPro), which is a special device used to replace a damaged cornea. Glaucoma can cause serious vision problems after KPro surgery, so doctors want to know if putting in a small drainage device to lower eye pressure at the same time as the KPro surgery is more effective than waiting six months to do it. The trial will involve 40 patients who meet certain criteria, such as having had previous corneal transplants that didn't work well and having poor vision in the affected eye.
Participants in the trial can expect to be closely monitored before and after their surgeries over the course of a year. They will have regular eye exams and tests to check their vision and eye health. This study aims to find out which timing for the drainage device leads to better eye pressure control and vision outcomes, helping future patients make informed choices about their treatment. If you're considering participating, it's important to know that you should be at least 18 years old and in good condition for surgery, but if you have severe glaucoma or serious retinal disease, you may not be eligible.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Candidate for corneal transplantation due to loss of corneal clarity
- • Verifiable history of one or more previous full thickness donor corneal transplantation failure
- • Pre-operative visual acuity of ≤20/80 or worse in the surgical eye
- • Age ≥18 years
- • Physical condition suitable for undergoing surgery
- Exclusion Criteria:
- • Terminal glaucoma
- • Terminal retinal diseases
About Centre Hospitalier De L'université De Montréal (Chum)
The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Mona Harissi-Dagher, MD, FRCSC
Principal Investigator
Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials